Impact of the COVID-19 Pandemic on the Organization of Healthcare in France

NCT05013047 | Unknown

• 1 other identifier: 2021-13
• Study Type: observational
• Target: 100,000
• Locations: 1 country
• Sites: 1

Brief Summary

The 2020 COVID-19 pandemic, which began spreading on January 24, 2020 in France, has required a profound and rapid reorganization of the health system, based in particular on internal hospital reorganizations of front-line establishments, deprogramming of non-urgent activities, and transfers of non-covid19 patients to 2nd line facilities. Beyond the immediate impact on the management of patients infected with COVID-19, this reorganization may have reduced the capacity of management for patients requiring urgent or semi-urgent intervention, or may have postponed some necessary care. The isolation of patients at home may also have resulted in lower compliance to therapy and medical treatments and may have contributed to decompensation. At the end of this crisis, the different organizational responses in France should be evaluated to identify the consequences and the areas for improvement in order to be prepared for future exceptional health situations. This investigation on healthcare systems confronted to an exceptional health situation thus seeks to determine if the profound reorganizations implemented during this health crisis have indirect effects on the performance of care, in particular if there is a destabilization of the care systems (emergency, semi-emergency and chronic), a loss of chance for the patients and if innovative care paths have emerged.

Conditions

COVID-19

Outcome Measures

Primary Outcomes (1)

• Assess the effect of pandemic COVID-19 on medication compliance in patients with chronic disease

  Combined chronic drug coverage rate calculated on a three-monthly basis (average of the coverage rates for each drug)

  Measured by trimesters (from March 2019 to February 2021)

Secondary Outcomes (1)

• Evaluate the effects of pandemic and lock-down on the risk of decompensation in patients with chronic disease.

  6 months period

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients without a symptomatic COVID-19 diagnosis, monitored for chronic disease in the French health care system.

You may qualify if:

• Patients with one of these three types of chronic diseases (Prevention Quality Indicators of the Agency for Healthcare Research and Quality): heart failure, diabetes, chronic obstructive pulmonary disease.
• All French adult patients suffering from the studied chronic diseases, covered by the Health Insurance and living in metropolitan France are included.

You may not qualify if:

• Patients under 18 years of age or with incomplete or inconsistent data on the "Système National des Données de Santé", or with a symptomatic COVID-19 diagnosis.

Sponsors & Collaborators

• Assistance Publique Hopitaux De Marseille: lead

Study Sites (1)

Assistance Publique Hôpitaux de Marseille

Marseille, 13354, France

RECRUITING

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Laurent BOYER

CONTACT

04 91 38 75 83; laurent.boyer@ap-hm.fr

Emilie GARRIDO-PRADALIE

CONTACT

Emilie.GARRIDO-PRADALIE@ap-hm.fr

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 18, 2021
• First Posted: August 19, 2021
• Study Start: July 1, 2020
• Primary Completion: July 1, 2022
• Study Completion: December 31, 2022
• Last Updated: August 24, 2021

Record last verified: 2021-08

Locations

FR (1)